452
Participants
Start Date
January 11, 2021
Primary Completion Date
August 31, 2029
Study Completion Date
August 31, 2032
Lymph node dissection
Open/minimaly invasive pelvic and para-aortic lymph node dissection
Standard chemoradiation±pembrolizumab
1\. A point/HCR-CTV D90≥80Gy(+20%).2. Extended-field EBRT: image-positive common iliac LN with SD≥10mm and/or image-positive PALN.3. Target doses for the image-positive nodes can range from 55 to 60Gy.4. Concurrent 5 cycles platinum-containing chemotherapy(Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w).5. CCRT will be completed in 56 days.6. The patients who received combined immunotherapy were treated with pembrolizumab (200mg, q3w, 3 cycles) during CCRT.7.After CCRT if the cervix biopsy shows residual tumor and/or imaging indicates that there are still positive LN with SD≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TAX 135mg/m2, DDP 50mg/m2, q3w or TAX 135mg/m2, CBP AUC=4, q3W) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) ± pembrolizumab(suitable for the patients who combined immunotherapy,200mg, q3w, 3 cycles) will be performed.8.Maintenance treatment with pembrolizumab (400mg, q6w) is optional for the combined immunotherapy patiants.
Chemoradiation± pembrolizumab
1\. A point/HCR-CTV D90≥80Gy(+20%).2. Extended-field EBRT: image-positive common iliac LN with SD≥10mm and/or image-positive PALN.3. Target doses for the image-positive nodes can range from 55 to 60Gy.4. Concurrent 5 cycles platinum-containing chemotherapy(Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w).5. CCRT will be completed in 56 days.6. The patients who received combined immunotherapy were treated with pembrolizumab (200mg, q3w, 3 cycles) during CCRT.7.After CCRT if the cervix biopsy shows residual tumor and/or imaging indicates that there are still positive LN with SD≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TAX 135mg/m2, DDP 50mg/m2, q3w or TAX 135mg/m2, CBP AUC=4, q3W) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) ± pembrolizumab(suitable for the patients who combined immunotherapy,200mg, q3w, 3 cycles) will be performed.8.Maintenance treatment with pembrolizumab (400mg, q6w) is optional for the combined immunotherapy patiants.
RECRUITING
Chongqing Cancer Hospital, Chongqing
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER
Jiangxi Provincial Cancer Hospital
OTHER
Anhui Provincial Cancer Hospital
OTHER
The Second Affiliated Hospital of Harbin Medical University
OTHER
Hebei Medical University Fourth Hospital
OTHER
Zhejiang Cancer Hospital
OTHER
Women's Hospital School Of Medicine Zhejiang University
OTHER
Qilu Hospital of Shandong University
OTHER
Fujian Cancer Hospital
OTHER_GOV
Sichuan Cancer Hospital and Research Institute
OTHER
Cancer Hospital of Guizhou Province
OTHER
West China Second University Hospital
OTHER
Tongji Hospital
OTHER
The Affiliated Ganzhou Hospital of Nanchang University
OTHER
First Affiliated Hospital of Gannan Medical University
OTHER
Gansu Provincial Maternal and Child Health Care Hospital
OTHER
Third Affiliated Hospital of Xinjiang Medical University
OTHER
Affiliated Cancer Hospital of Shantou University Medical College
OTHER
Obstetrics & Gynecology Hospital of Fudan University
OTHER
The Second Affiliated Hospital of Dalian Medical University
OTHER
Fujian Maternity and Child Health Hospital
OTHER
Shandong Cancer Hospital and Institute
OTHER
Sun Yat-sen University Cancer Hosptial
UNKNOWN
Chongqing University Cancer Hospital
OTHER